These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11526907)

  • 1. 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties.
    Skerra A
    J Biotechnol; 2001 Jun; 74(4):257-75. PubMed ID: 11526907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipocalins as a scaffold.
    Skerra A
    Biochim Biophys Acta; 2000 Oct; 1482(1-2):337-50. PubMed ID: 11058774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
    Skerra A
    FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticalins small engineered binding proteins based on the lipocalin scaffold.
    Gebauer M; Skerra A
    Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of anticalins with specificity for a nonsymmetric phthalic acid ester.
    Mercader JV; Skerra A
    Anal Biochem; 2002 Sep; 308(2):269-77. PubMed ID: 12419339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticalins as an alternative to antibody technology.
    Schlehuber S; Skerra A
    Expert Opin Biol Ther; 2005 Nov; 5(11):1453-62. PubMed ID: 16255649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.
    Richter A; Eggenstein E; Skerra A
    FEBS Lett; 2014 Jan; 588(2):213-8. PubMed ID: 24239535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant -- a so-called 'anticalin' -- using a molecular random approach.
    Schlehuber S; Skerra A
    Biophys Chem; 2002 May; 96(2-3):213-28. PubMed ID: 12034442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold.
    Beste G; Schmidt FS; Stibora T; Skerra A
    Proc Natl Acad Sci U S A; 1999 Mar; 96(5):1898-903. PubMed ID: 10051566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of ribosome display library based on lipocalin scaffold and screening anticalins with specificity for estradiol.
    Liu J; Ning B; Liu M; Sun Y; Sun Z; Zhang Y; Fan X; Zhou Z; Gao Z
    Analyst; 2012 May; 137(10):2470-9. PubMed ID: 22489281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystallographic analysis of an "anticalin" with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region.
    Korndörfer IP; Beste G; Skerra A
    Proteins; 2003 Oct; 53(1):121-9. PubMed ID: 12945055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin.
    Schlehuber S; Beste G; Skerra A
    J Mol Biol; 2000 Apr; 297(5):1105-20. PubMed ID: 10764576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticalins in drug development.
    Schlehuber S; Skerra A
    BioDrugs; 2005; 19(5):279-88. PubMed ID: 16207069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticalins versus antibodies: made-to-order binding proteins for small molecules.
    Weiss GA; Lowman HB
    Chem Biol; 2000 Aug; 7(8):R177-84. PubMed ID: 11048945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural plasticity in the loop region of engineered lipocalins with novel ligand specificities, so-called Anticalins.
    Achatz S; Jarasch A; Skerra A
    J Struct Biol X; 2022; 6():100054. PubMed ID: 34988429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold.
    Schlehuber S; Skerra A
    Biol Chem; 2001 Sep; 382(9):1335-42. PubMed ID: 11688717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticalins as alternative binding proteins for therapeutic use.
    Skerra A
    Curr Opin Mol Ther; 2007 Aug; 9(4):336-44. PubMed ID: 17694446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds.
    Schiefner A; Skerra A
    Acc Chem Res; 2015 Apr; 48(4):976-85. PubMed ID: 25756749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.
    Hohlbaum AM; Skerra A
    Expert Rev Clin Immunol; 2007 Jul; 3(4):491-501. PubMed ID: 20477155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMR structure and dynamics of the engineered fluorescein-binding lipocalin FluA reveal rigidification of beta-barrel and variable loops upon enthalpy-driven ligand binding.
    Mills JL; Liu G; Skerra A; Szyperski T
    Biochemistry; 2009 Aug; 48(31):7411-9. PubMed ID: 19603796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.